Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE:300434) signed Equity Acquisition agreement to acquire 65.40% stake in Zhejiang Jiande Zhengfa Pharmaceutical Co.Ltd from group of shareholders for approximately CNY 150 million on April 25, 2021. Consideration will be paid in cash. At the same time, after the completion of this equity transfer, the company plans to increase capital to the target company with CNY 36 million, of which 7.37 million is included in the target company’s registered capital and 28.63 million is included in the target company’s capital reserve. Sichuan Goldstone Asia Pharmaceutical held the second meeting of the fourth board of directors on April 25, 2021, and reviewed and approved the transaction and also obtained the "Business License" issued by the Jiande City Market Supervision Administration.